

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM627487

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Eton Pharmaceuticals, Inc.		02/04/2021	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Azurity Pharmaceuticals, Inc.		
<b>Street Address:</b>	8 Cabot Road, Suite 2000		
<b>City:</b>	Woburn		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	01801		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88061929	HODUCA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6176468646		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	617-646-8000		
<b>Email:</b>	drwtrademarks@wolfgreenfield.com		
<b>Correspondent Name:</b>	Douglas R. Wolf		
<b>Address Line 1:</b>	600 Atlantic Avenue		
<b>Address Line 2:</b>	Wolf, Greenfield & Sacks, P.C.		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02210		
<b>ATTORNEY DOCKET NUMBER:</b>	C1047.20040US00		
<b>NAME OF SUBMITTER:</b>	Douglas R. Wolf		
<b>SIGNATURE:</b>	/drw/		
<b>DATE SIGNED:</b>	02/22/2021		
<b>Total Attachments: 1</b>			
source=C1047.20040US00 - Assignment from Eton to Azurity#page1.tif			

OP \$40.00 88061929

**ASSIGNMENT**

For fair and valuable consideration, **Eton Pharmaceuticals, Inc.** ("Assignor"), 21925 West Field Parkway, Suite 235, Deer Park, IL 60010, a corporation of Delaware, U.S.A., hereby sells, assigns and transfers unto **Azurity Pharmaceuticals, Inc.** ("Assignee"), 8 Cabot Road, Suite 2000, Woburn, MA 01801, a corporation of Delaware, U.S.A., and its successors and assigns, the whole right, title and interest in the mark:

**HODUCA**, SN: 88-61929, Intent to Use Allowance issued February 26, 2019,  
together with all associated good will of the business interests symbolized by the Trademark.

**Eton Pharmaceuticals, Inc.**

Signature(s): Sean Brynjelsson

Name(s): Sean Brynjelsson

Title(s): CEO

Date: 02 / 04 / 2021